Biobehavioral and Sociodemographic Characteristics of Long Term Survivors of Ovarian Cancer
The goal of this research study is to learn about diet and exercise habits, emotions, and social support in the lives of women with ovarian cancer.
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Biobehavioral and Sociodemographic Characteristics of Long Term Survivors of Ovarian Cancer|
- Biobehavioral Information Collection in Ovarian Cancer Survivors [ Time Frame: 1 day ] [ Designated as safety issue: No ]Biobehavioral information collected regarding social support, depressed mood, life stress, quality of life, meaning in life, socioeconomic and relationship status, and lifestyle factors such as exercise and diet, which have been linked with cancer progression and/or survival in cancer patients.
|Study Start Date:||January 2014|
|Estimated Primary Completion Date:||January 2020 (Final data collection date for primary outcome measure)|
Ovarian Cancer Survivors
Short-term and long-term ovarian cancer survivors
Questionnaire completion asking questions about quality of life, mood, social support, stress, diet, lifestyle, and demographic information. Questionnaire should take about 60-90 minutes to complete.
Other Name: SurveyBehavioral: Interview
Interview asking questions about the amount of stress participant may be having or have had in the past. It should take about 25-30 minutes to complete the interview.
If you agree to take part in this study, you will fill out a questionnaire, complete an interview, and information will be collected from your medical record.
For the questionnaire, you will answer questions about your quality of life, mood, social support, stress, diet, lifestyle, and demographic information (such as your age and race). The questionnaire should take about 60-90 minutes to complete.
The interview may be done during a routine visit at MD Anderson or by phone. A trained interviewer will ask you questions about the amount of stress you may be having or have had in the past. It should take about 25-30 minutes to complete the interview.
Information collected from your medical record will include the status of the disease, if the disease has gotten worse, any treatments you have received, and any side effects you may have had. This information will help researchers learn how specific treatments may affect patients.
If you are already enrolled in a protocol in which you will be having tumor tissue collected for future analysis, the information gathered in those studies will be used together with the data collected for this study to learn if behavioral factors relate to your tumor tissue test results.
Length of Study:
Your study participation will be over after completing the questionnaire and interview.
For quality control purposes, a random sample of interviews may be tape recorded. Before any information is recorded, you will be asked for your permission.
The tape recording will be done by members of the study staff. Your audiotape will be given a code number. No identifying information (such as your name and medical record number) will be recorded on the audiotape.
This is an investigational study.
Up to 210 participants will be enrolled in this multicenter study. Up to 90 will take part at MD Anderson.
Please refer to this study by its ClinicalTrials.gov identifier: NCT02043158
|Contact: Eileen H. Shinn, PHD, MS, BA||713-745-0870|
|United States, California|
|West Hollywood, California, United States, 90048|
|Contact: Marc Goodman, Ph.D.|
|United States, Iowa|
|University of Iowa||Recruiting|
|Iowa City, Iowa, United States, 52242|
|Contact: Susan Lutgendorf, Ph.D.|
|United States, New York|
|Memorial Sloan Kettering||Recruiting|
|New York, New York, United States, 10065|
|Contact: Jeanne Carter, Ph.D.|
|United States, Oklahoma|
|University of Oklahoma||Recruiting|
|Norman, Oklahoma, United States, 73019|
|Contact: Maryanne Matzo, Ph.D.|
|United States, Texas|
|University of Texas MD Anderson Cancer Center||Recruiting|
|Houston, Texas, United States, 77030|
|Principal Investigator:||Eileen H. Shinn, PHD, MS, BA||M.D. Anderson Cancer Center|